sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
agttggaacttaatttgagacag | 322 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttggaacttaatttgagacag | 322 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttggaacttaatttgagacag | 142 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttggaacttaatttgagacag | 142 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
agttggaacttaatttgagacag | 142 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attcaatacaacctgctcttaaa | 1174 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attcaatacaacctgctcttaaa | 1174 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attcaatacaacctgctcttaaa | 1174 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attcaatacaacctgctcttaaa | 810 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attcaatacaacctgctcttaaa | 810 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
attcaatacaacctgctcttaaa | 810 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatagttaagttctgaggaaaa | 804 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatagttaagttctgaggaaaa | 804 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatagttaagttctgaggaaaa | 804 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatagttaagttctgaggaaaa | 1168 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatagttaagttctgaggaaaa | 1168 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatagttaagttctgaggaaaa | 1168 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtttcactaaatgtcacttgtgt | 437 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtttcactaaatgtcacttgtgt | 437 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtttcactaaatgtcacttgtgt | 437 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgagttctcatttagttgact | 1690 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgagttctcatttagttgact | 1690 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgagttctcatttagttgact | 1690 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgagttctcatttagttgact | 1598 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgagttctcatttagttgact | 1598 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tgagttctcatttagttgact | 1598 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aggacccaaattatgaggaaact | 1805 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aggacccaaattatgaggaaact | 1805 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aggacccaaattatgaggaaact | 1805 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatcaactatttccagacaatt | 373 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatcaactatttccagacaatt | 373 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aaatcaactatttccagacaatt | 373 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gggactggtttaacccttactta | 1792 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gggactggtttaacccttactta | 1792 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gggactggtttaacccttactta | 1792 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actttgtagtcaagatgaatgac | 147 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actttgtagtcaagatgaatgac | 147 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actttgtagtcaagatgaatgac | 147 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actttgtagtcaagatgaatgac | 327 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actttgtagtcaagatgaatgac | 327 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
actttgtagtcaagatgaatgac | 327 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtaaccagattttcctaatat | 523 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtaaccagattttcctaatat | 523 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtaaccagattttcctaatat | 523 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtaaccagattttcctaatat | 885 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtaaccagattttcctaatat | 885 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gtaaccagattttcctaatat | 885 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gaaagaatctctcgctttgcaaa | 1744 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gaaagaatctctcgctttgcaaa | 1744 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gaaagaatctctcgctttgcaaa | 1744 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gaaagaatctctcgctttgcaaa | 1652 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gaaagaatctctcgctttgcaaa | 1652 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
gaaagaatctctcgctttgcaaa | 1652 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aactctagaaatatctggtccaa | 1092 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aactctagaaatatctggtccaa | 1092 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aactctagaaatatctggtccaa | 1092 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aactctagaaatatctggtccaa | 730 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aactctagaaatatctggtccaa | 730 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
aactctagaaatatctggtccaa | 730 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttatggagtgaaaataaaagt | 534 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttatggagtgaaaataaaagt | 534 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttatggagtgaaaataaaagt | 534 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttatggagtgaaaataaaagt | 896 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttatggagtgaaaataaaagt | 896 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ttatggagtgaaaataaaagt | 896 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tcacgttaagctaattttaaact | 445 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tcacgttaagctaattttaaact | 445 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
tcacgttaagctaattttaaact | 445 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagttctcttctatgcaagt | 79 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagttctcttctatgcaagt | 79 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagttctcttctatgcaagt | 79 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagttctcttctatgcaagt | 259 | EP4161532A2 | IRNA-ZUSAMMENSETZUNGEN AUS TUMORNEKROSEFAKTORREZEPTORASSOZIIERTEM FAKTOR 6 (TRAF6) UND VERFAHREN ZUR VERWENDUNG DAVON | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagttctcttctatgcaagt | 259 | EP4161532A2 | Tumor necrosis factor receptor associated factor 6 (TRAF6) irna compositions and methods of use thereof | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
atagttctcttctatgcaagt | 259 | EP4161532A2 | COMPOSITIONS D'ARNI DU FACTEUR 6 ASSOCIÉ AU RÉCEPTEUR DU FACTEUR DE NÉCROSE TUMORALE (TRAF6) ET LEURS MÉTHODES D'UTILISATION | 20,230,412 | 1 | [
"US",
"EP",
"HK",
"WO"
] | null |
ucucuggacuacggcuuggcu | 71 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
ucucuggacuacggcuuggcu | 71 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
ucucuggacuacggcuuggcu | 2025 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
ucucuggacuacggcuuggcu | 2025 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
ucucuggacuacggcuuggcu | 1142 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
ucucuggacuacggcuuggcu | 1142 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
ucucuggacuacggcuuggcu | 323 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
ucucuggacuacggcuuggcu | 323 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
cuggagaagaggcucaucacu | 733 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
cuggagaagaggcucaucacu | 733 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
cuggagaagaggcucaucacu | 2018 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
cuggagaagaggcucaucacu | 2018 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
cuggagaagaggcucaucacu | 1130 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
cuggagaagaggcucaucacu | 1130 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
auagcgguaacaacccagcgugg | 1818 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
auagcgguaacaacccagcgugg | 1818 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
auagcgguaacaacccagcgugg | 2243 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
auagcgguaacaacccagcgugg | 2243 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
aagccagugugaaagacauagcu | 1549 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
aagccagugugaaagacauagcu | 1549 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
agucuuucacacuggcuuccagg | - | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
agucuuucacacuggcuuccagg | - | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
aagacaagaugccaccuccugcc | 255 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
aagacaagaugccaccuccugcc | 255 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
aagacaagaugccaccuccugcc | 507 | WO2022231999A1 | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
aagacaagaugccaccuccugcc | 507 | WO2022231999A1 | COMPOSITIONS D'ARNI DE PROTÉASE TRANSMEMBRANAIRE, DE SÉRINE 6 (TMPRSS6) ET LEURS PROCÉDÉS D'UTILISATION | 20,221,103 | 224 | [
"MX",
"MY",
"CO",
"ZA",
"JP",
"CN",
"BR",
"CL",
"EP",
"EA",
"IL",
"US",
"CA",
"HK",
"NZ",
"SG",
"IN",
"AU",
"WO",
"KR",
"TW"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.